Table 2.
Variable | Quartile 1 |
Quartile2 |
Quartile 3 |
Quartile 4 |
P for Trendc |
|||||
---|---|---|---|---|---|---|---|---|---|---|
ADPKD | HC | ADPKD | HC | ADPKD | HC | ADPKD | HC | ADPKD | HC | |
Age (years) | 27 ± 5 | 28 ± 5 | 35 ± 2 | 36 ± 2 | 43 ± 3 | 43 ± 3 | 54 ± 5 | 54 ± 5 | <0.001 | <0.001 |
Male gender, n (%) | 16 (64) | 16 (64) | 16 (55) | 16 (55) | 12 (46) | 12 (46) | 16 (62) | 16 (62) | 0.6 | 0.6 |
BMI (kg/m2) | 25.1 ± 4.7 | 25.2 ± 3.3 | 26.4 ± 5.2 | 25.4 ± 4.0 | 25.1 ± 3.3 | 24.8 ± 3.4 | 27.4 ± 4.6 | 26.9 ± 4.3 | 0.2 | 0.66 |
MAP (mmHg) | 96 ± 11 | 91 ± 12 | 96 ± 7b | 89 ± 6 | 96 ± 11 | 91 ± 7 | 97 ± 9 | 95 ± 10 | 0.9 | 0.2 |
Antihypertensive medicine, n (%) | 15 (60)b | 1 (4) | 23 (79)b | 0 (0) | 19 (73)b | 0 (0) | 24 (92)b | 1 (4) | 0.05 | 1.0 |
ACEI/ARB, n (%) | 14 (56)b | 0 (0) | 19 (73)b | 0 (0) | 18 (69)b | 0 (0) | 21 (81)b | 0 (0) | 0.3 | 1.0 |
TRV (L) | 1.0 (0.7 to 2.0) | – | 1.6 (1.1 to 2.5) | – | 1.6 (1.1 to 2.1) | – | 1.6 (1.1 to 2.2) | – | 0.1 | – |
Hb (mmol/L) | 8.5 ± 0.7b | 9.0 ± 0.8 | 8.3 ± 0.8b | 9.0 ± 1.0 | 8.3 ± 0.8 | 8.7 ± 0.9 | 8.4 ± 1.0b | 8.9 ± 0.8 | 0.9 | 0.04 |
Serum creatinine (μmol/L) | 93 ± 46b | 73 ± 11 | 102 ± 56b | 74 ± 10 | 107 ± 63b | 71 ± 11 | 145 ± 92b | 78 ± 13 | 0.04 | 0.2 |
GFR (ml/min) | 117 ± 32 | 129 ± 17 | 102 ± 30b | 130 ± 16 | 84 ± 32b | 122 ± 24 | 74 ± 47b | 116 ± 18 | <0.001 | 0.04 |
ERPF (ml/min) | 374 ± 119b | 527 ± 83 | 335 ± 103b | 491 ± 68 | 287 ± 116b | 454 ± 88 | 203 ± 104b | 429 ± 62 | <0.001 | <0.001 |
FF | 32 ± 4b | 25 ± 2 | 31 ± 4b | 26 ± 3 | 29 ± 4b | 27 ± 4 | 30 ± 4b | 27 ± 2 | 0.1 | 0.007 |
RVR (dynes/cm−2) | 12 (10 to 16)b | 8 (7 to 9) | 14 (11 to 17)b | 8 (7 to 9) | 17 (13 to 21)b | 10 (8 to 12) | 22 (18 to 33)b | 10 (9 to 11) | <0.001 | <0.001 |
HC, healthy control.
Parametric variables are expressed as mean ± SD, whereas nonparametric variables are given as median (25th to 75th percentile).
P < 0.05 between ADPKD and healthy controls.
P values obtained using ANOVA/Kruskal–Wallis.